Evidence map›Paper›PMID 34927122›Full record

ArticleNeuroimage. Reports2021

Vascular risk is not associated with PET measures of Alzheimer's disease neuropathology among cognitively normal older adults.

Murat Bilgel, Alisa Bannerjee, Andrea Shafer, Yang An, Susan M Resnick

Open access · goldAbstract read
In one paragraph

Article in Neuroimage. Reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 2 pooled it
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 2 syntheses or guidelines pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Hypertension and Alzheimer's disease pathology at autopsy: A systematic review.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2022
    Pooled it
  3. The vascular contribution to dementia: World Stroke Organization scientific statement.International journal of stroke : official journal of the International Stroke Society · 2026
    Review
  4. Elevated AD biomarkers do not explain cognitive performance in a community-recruited clinical trial cohort.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  5. The performance of plasma p-tau217 in Black middle-aged and older adults.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Trajectory of clinical symptoms in relation to amyloid chronicity.Alzheimer's & dementia (Amsterdam, Netherlands) · 2022
    Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Murat BilgelLaboratory of Behavioral Neuroscience, National Institute on Aging, NIH.
Alisa BannerjeeLaboratory of Behavioral Neuroscience, National Institute on Aging, NIH.
Andrea ShaferLaboratory of Behavioral Neuroscience, National Institute on Aging, NIH.
Yang AnLaboratory of Behavioral Neuroscience, National Institute on Aging, NIH.
Susan M ResnickLaboratory of Behavioral Neuroscience, National Institute on Aging, NIH.
National Institute on Aging · US

Funding

Research Education ComponentP30AG066507 · NIA · JOHNS HOPKINS UNIVERSITY · PI MARILYN S. ALBERT · 2020 to 2026
$29.3M
Intramural NIH HHS Z99 AG999999NIA NIH HHS P30 AG066507
6 · The paper itself

Abstract

Cardiovascular disease (CVD) is associated with a higher risk of developing dementia. Studies have found that vascular risk factors are associated with greater amyloid-β (Aβ) and tau burden, which are hallmark neuropathologies of Alzheimer's disease (AD). Evidence for these associations during the preclinical stages of AD, when Aβ and tau pathologies first become detectable, is mixed. Quantifying the effect of vascular risk among cognitively normal individuals can help focus the efforts to develop therapeutic approaches aimed at modifying the course of preclinical AD. Using Bayesian analysis, we examined the relationship of Aβ and tau pathology with concurrent vascular risk among 87 cognitively normal individuals (median age 77, interquartile range 70-83) in the Baltimore Longitudinal Study of Aging. We quantified vascular risk as the probability of developing CVD within 10 years using published equations from the Framingham Heart Study. Aβ and tau pathologies were measured using positron emission tomography. As expected, Aβ positive participants had greater tau in the entorhinal cortex (EC) and inferior temporal gyrus (ITG) (difference in means = 0.09, p < 0.05 for each region), and 10-year CVD risk was positively correlated with white matter lesion burden (r = 0.24, p = 0.03). However, we did not find any associations between CVD risk and Aβ or tau. The data provided over two- and four-fold evidence towards the lack of a correlation between CVD risk and tau in the EC (Bayes factor BF = 2.4) and ITG (BF = 4.0), respectively. We found over three-fold evidence towards the lack of a difference in mean CVD risk by Aβ group (BF = 3.4). These null findings were replicated using a data-driven vascular risk score in the BLSA based on a principal component analysis of eight indicators of vascular health. Our data provide moderate evidence towards the lack of an association between vascular risk and concurrent AD neuropathology among cognitively normal older adults. This finding suggests that vascular risk and AD neuropathology may constitute independent pathways in the development of cognitive impairment and dementia.

Indexed as

agingamyloidBayes theoremcardiovascular diseasescognitively normalpositron emission tomographytautemporal lobe

Identifiers

PMID34927122
PMCPMC8682073
OpenAlexW3217561425

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.